ArticleBMC public health2015
Metabolic syndrome and prostate cancer risk in a population-based case-control study in Montreal, Canada.
Article in BMC public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 83 citations in OpenAlex.
- Association between blood pressure and risk of cancer development: a systematic review and meta-analysis of observational studies.Scientific reports · 2019Pooled it
- Metabolic Dysfunction After Initiation of Androgen Receptor Pathway Inhibitors in Prostate Cancer.JAMA oncology · 2026Article
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.JAMA network open · 2026Article
- From obesity to inflammation: emerging frontiers in prostate cancer and metabolic syndrome studies.Translational andrology and urology · 2025Article
- Understanding the role of metabolic syndrome in prostate cancer risk: A UK Biobank prospective cohort study.Scientific reports · 2025Article
- The effect between metabolic syndrome and life expectancy after cancer diagnosis: Catalan cohort study.BMC public health · 2025Article
- Machine learning algorithms that predict the risk of prostate cancer based on metabolic syndrome and sociodemographic characteristics: a prospective cohort study.BMC public health · 2024Article
- Exploring the association between metabolic syndrome, its components and subsequent cancer incidence: A cohort study in Catalonia.Cancer medicine · 2024Article
- Causal relationship between prostatic diseases and prostate cancer: a mendelian randomization study.BMC cancer · 2024Article
- Dyslipidemia: prevalence and association with precancerous and cancerous lesions of the cervix; a pilot study.Lipids in health and disease · 2024Article
- Association between body mass index, metabolic syndrome and common urologic conditions: a cross-sectional study using a large multi-institutional database from the United States.Annals of medicine · 2023Article
- Neighbourhood social deprivation and risk of prostate cancer.British journal of cancer · 2023Article
- The influence of lifestyle changes (diet, exercise and stress reduction) on prostate cancer tumour biology and patient outcomes: A systematic review.BJUI compass · 2023Review
- Predictors of Prostate Cancer at Fusion Biopsy: The Role of Positive Family History, Hypertension, Diabetes, and Body Mass Index.Current oncology (Toronto, Ont.) · 2023Article
- Projection of Premature Cancer Mortality in Hunan, China, Through 2030: Modeling Study.JMIR public health and surveillance · 2023Article
- Role of Metabolism and Metabolic Pathways in Prostate Cancer.Metabolites · 2023Review
- Article
- Comparison of mixed model based approaches for correcting for population substructure with application to extreme phenotype sampling.BMC genomics · 2022Article
- Overweight and obesity as risk factors for biochemical recurrence of prostate cancer after radical prostatectomy.International journal of clinical oncology · 2022Article
- Association between metabolic syndrome and 13 types of cancer in Catalonia: A matched case-control study.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe role of metabolic syndrome (MetS) in prostate cancer risk is still debated. We investigated it in a large population-based case-control study.
methodsCases were 1937 men with incident prostate cancer, aged ≤ 75 years, diagnosed across French hospitals in the Montreal area between 2005 and 2009. Concurrently, 1995 population controls from the same residential area and age distribution were randomly selected from electoral list of French-speaking men. Detailed lifestyle and medical histories, and anthropometric measures, were collected during in-person interviews. Prevalence of MetS components (type 2 diabetes, high blood pressure, dyslipidemia and abdominal obesity) was estimated at 2 years before diagnosis for cases/ interview for controls, and at ages 20, 40, 50 and 60. Logistic regression was used to estimate odds ratios (OR) and 95 % confidence intervals for the association between MetS and prostate cancer risk.
resultsA history of MetS (≥ 3 components vs < 3) was associated with a reduced risk of prostate cancer (OR = 0.70 [0.60, 0.82]) after considering potential confounders. The negative association was particularly pronounced with a young age (≤ 40 years) at MetS onset (OR = 0.38 [0.16-0.89]), did not vary according to prostate cancer aggressiveness, and was only partly explained by the presence of type 2 diabetes. A risk decrease was observed with the number of MetS components, suggesting a synergistic interaction of the components. DISCUSSION: The observed negative association, consistent with results from other North American populations undergoing regular prostate cancer screening, underlines the importance of considering PSA-testing when studying the MetS-prostate cancer association.
conclusionsFindings from this study are consistent with an inverse association between MetS and prostate cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.